The green light comes on the back of the phase 3 ARCHWAY trial which showed that Susvimo was equivalent to monthly Lucentis injections at maintaining vision in patients over 40 weeks, with 98% of ...

Patients requiring frequent ranibizumab intravitreal injections for various indications as part of their routine clinical care were recruited to partake in this study. The primary goal of the ...

MiscellaneousFormycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz) 19.05.2025 / 15:00 CET/CESTThe issuer is solely responsible for the content ...

Lucentis' main patents are not due to expire ... intervals between dosing - an attractive proposition for patients as injections need to be administered into the eye - but has been affected ...

Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced today that the U.S. Food and Drug Administration (FDA) designated Otulfi® (ustekinumab-aauz) as an interchangeable ...

LYTENAVA (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom (UK) in Q2 CY2025Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in th ...

Currently, off-label repackaged bevacizumab is one of the most frequently used first-line anti-VEGF treatments in Europe (approximately 2.8 million injections annually ... study evaluating ONS-5010 ...

“But, it's exciting to get an injection of youth to go along with a lot of the veterans that we have on this football team. So, it's exciting. It's going to be fun to work with them.” The ...

The This Morning star, 50, admitted she was initially scared of using weight loss injections after learning more about them. She feels that perhaps they are not the right option for her at this ...

consistent safetyONS-5010 demonstrated to be non-inferior to Lucentis at 4 and 12 weeksCompany on track for anticipated BLA resubmission in calendar Q1 2025 ISELIN, N.J., Jan. 23, 2025 (GLOBE ...